Interestingly, in case 3 (mild IPF and severe PH), many clinicians chose dual therapy with a PDE5 inhibitor and an ERA, despite evidence that the use of ERAs could worsen hypoxia without an increase in efficacy (18, 19). This evidence concerns the gene PDE5A and idiopathic pulmonary fibrosis.